Skip Navigation LinksHome > July 2012 - Volume 7 - Issue 4 > Current advances in pharmacovigilance in the USA and Europe:...
Current Opinion in HIV & AIDS:
doi: 10.1097/COH.0b013e328354dcac
PHARMACOVIGILANCE OF ANTI-HIV DRUGS: Edited by Ian Weller

Current advances in pharmacovigilance in the USA and Europe: meeting the challenges of safety monitoring in HIV

Marcus, Kendall A.a; Sorbello, Alfredb; Truffa, Melissab; Williams, Juliec; Raine, June M.c; Powderly, William G.d

Collapse Box

Abstract

Purpose of review: The success of antiretroviral therapy in HIV disease comes currently with the realization that patients are committed to life-long treatment, which raises the possibility of long-term toxicity. Such long-term side effects may not be identified in initial clinical trials requiring, therefore, a different approach to monitoring patients over time – a pharmacovigilance approach.

Recent findings: Several key issues in long-term management of HIV infection have been addressed by a pharmacovigilance approach – including unusual and rare side effects and elucidation of emerging toxicities such as cardiovascular, bone and renal disease. Recent changes in legislation in the USA and Europe are aimed to strengthen pharmacovigilance in developed countries.

Summary: HIV infection and its treatment provide an important example of the role of pharmacovigilance. As clinical trials can rarely address the question of long-term tolerability, effective pharmacovigilance programs are and will remain essential.

© 2012 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.